Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MEREO BIOPHARMA GROUP PLC

(MREO)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
0.7672 USD   -2.01%
11/18Pharmaceutical Stocks Help European Equities Nudge Higher to End Quiet Week
MT
11/15European Markets Move Higher Helped by Upbeat US Inflation Data
MT
11/10SVB Securities Trims Price Target on Mereo BioPharma Group to $4 From $8, Maintains Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mereo BioPharma Says Rubric Capital Management Rejected Offer to Resolve Proxy Contest

09/26/2022 | 09:58am EST


ę MT Newswires 2022
All news about MEREO BIOPHARMA GROUP PLC
11/18Pharmaceutical Stocks Help European Equities Nudge Higher to End Quiet Week
MT
11/15European Markets Move Higher Helped by Upbeat US Inflation Data
MT
11/10SVB Securities Trims Price Target on Mereo BioPharma Group to $4 From $8, Maintains Out..
MT
11/08European ADRs Move Higher in Tuesday Trading, Adding to Monday's Gains
MT
11/08Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conf..
AQ
11/07European ADRs Rise in Monday Trading
MT
11/03European ADRs Regain Some Early Losses on Thursday
MT
11/02Mereo Biopharma : Condensed Consolidated Statements of Comprehensive (Loss)/Income - Form ..
PU
11/02Mereo BioPharma Group plc Reports Earnings Results for the Half Year Ended June 30, 202..
CI
11/02Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
AQ
More news
Analyst Recommendations on MEREO BIOPHARMA GROUP PLC
More recommendations
Financials
Sales 2022 - - -
Net income 2022 -9,99 M -12,1 M -12,1 M
Net cash 2022 41,6 M 50,3 M 50,3 M
P/E ratio 2022 -21,2x
Yield 2022 -
Capitalization 69,0 M 83,4 M 83,4 M
EV / Sales 2022 -
EV / Sales 2023 3,62x
Nbr of Employees 49
Free-Float 51,6%
Chart MEREO BIOPHARMA GROUP PLC
Duration : Period :
Mereo BioPharma Group plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEREO BIOPHARMA GROUP PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 63,47 GBX
Average target price 370,20 GBX
Spread / Average Target 483%
EPS Revisions
Managers and Directors
Denise Vera Scots-Knight Chief Executive Officer & Director
Christine Fox Chief Financial Officer
Michael S. Wyzga Chairman
John A. Lewicki Chief Scientific Officer
Suba Krishnan Senior Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
MEREO BIOPHARMA GROUP PLC-52.05%83
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930